Renaissance Technologies LLC increased its stake in Phibro Animal Health Corp (NASDAQ:PAHC) by 18.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 634,500 shares of the company’s stock after purchasing an additional 97,700 shares during the quarter. Renaissance Technologies LLC owned approximately 1.57% of Phibro Animal Health worth $29,219,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Victory Capital Management Inc. lifted its holdings in Phibro Animal Health by 15.9% in the 2nd quarter. Victory Capital Management Inc. now owns 8,095 shares of the company’s stock worth $373,000 after purchasing an additional 1,108 shares during the last quarter. FMR LLC lifted its holdings in Phibro Animal Health by 0.7% in the 2nd quarter. FMR LLC now owns 171,107 shares of the company’s stock worth $7,879,000 after purchasing an additional 1,109 shares during the last quarter. Swiss National Bank lifted its holdings in Phibro Animal Health by 5.3% in the 1st quarter. Swiss National Bank now owns 33,600 shares of the company’s stock worth $1,334,000 after purchasing an additional 1,700 shares during the last quarter. Campbell & CO Investment Adviser LLC lifted its holdings in Phibro Animal Health by 17.6% in the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 11,371 shares of the company’s stock worth $524,000 after purchasing an additional 1,700 shares during the last quarter. Finally, Citadel Advisors LLC lifted its holdings in Phibro Animal Health by 25.8% in the 1st quarter. Citadel Advisors LLC now owns 10,999 shares of the company’s stock worth $437,000 after purchasing an additional 2,254 shares during the last quarter. Hedge funds and other institutional investors own 49.20% of the company’s stock.

In other news, VP Daniel M. Bendheim sold 2,500 shares of the company’s stock in a transaction that occurred on Wednesday, September 12th. The stock was sold at an average price of $44.30, for a total transaction of $110,750.00. Following the completion of the transaction, the vice president now directly owns 2,500 shares in the company, valued at $110,750. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Jack Bendheim sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, June 27th. The stock was sold at an average price of $45.79, for a total value of $457,900.00. Following the transaction, the chief executive officer now owns 60,000 shares of the company’s stock, valued at $2,747,400. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 343,960 shares of company stock valued at $16,571,627. Corporate insiders own 51.88% of the company’s stock.

Several equities research analysts recently weighed in on the company. BidaskClub lowered Phibro Animal Health from a “hold” rating to a “sell” rating in a report on Tuesday. Zacks Investment Research upgraded Phibro Animal Health from a “sell” rating to a “buy” rating and set a $53.00 target price for the company in a report on Thursday, August 30th. Morgan Stanley boosted their target price on Phibro Animal Health from $36.00 to $46.00 and gave the stock an “underweight” rating in a report on Wednesday, August 29th. Finally, Barclays boosted their target price on Phibro Animal Health from $31.00 to $33.00 and gave the stock an “underweight” rating in a report on Thursday, July 5th. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $43.20.

Shares of PAHC stock opened at $42.65 on Thursday. Phibro Animal Health Corp has a 12 month low of $32.05 and a 12 month high of $54.62. The company has a market cap of $1.77 billion, a PE ratio of 25.14, a price-to-earnings-growth ratio of 2.53 and a beta of 0.89. The company has a debt-to-equity ratio of 1.62, a current ratio of 2.90 and a quick ratio of 1.66.

Phibro Animal Health (NASDAQ:PAHC) last issued its quarterly earnings results on Monday, August 27th. The company reported $0.46 EPS for the quarter, topping analysts’ consensus estimates of $0.42 by $0.04. Phibro Animal Health had a return on equity of 39.81% and a net margin of 7.90%. The company had revenue of $211.80 million during the quarter, compared to analyst estimates of $209.27 million. During the same period in the previous year, the company earned $0.39 earnings per share. The company’s quarterly revenue was up 8.7% compared to the same quarter last year. equities analysts anticipate that Phibro Animal Health Corp will post 1.8 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 26th. Stockholders of record on Wednesday, September 5th will be issued a dividend of $0.10 per share. The ex-dividend date of this dividend is Tuesday, September 4th. This represents a $0.40 dividend on an annualized basis and a dividend yield of 0.94%. Phibro Animal Health’s dividend payout ratio (DPR) is presently 22.99%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture.

Featured Article: How to interpret a stock’s beta number

Institutional Ownership by Quarter for Phibro Animal Health (NASDAQ:PAHC)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.